DEV Community: Ankit kumar

How KOL Insights Are Shaping the Future of Multiple Sclerosis Care

Ankit kumar — Fri, 14 Aug 2026 07:27:00 +0000

Multiple sclerosis (MS) management is evolving rapidly. Advances in high-efficacy therapies, biomarkers, digital monitoring, and artificial intelligence are creating new possibilities for earlier intervention and more personalized care.

But where is the field actually heading?

To explore this question, SPER Market Research conducted an MS KOL Perception Study focused on expert perspectives across the evolving multiple sclerosis treatment landscape.

The study examines how leading experts view treatment advances, remaining gaps, emerging technologies, and the priorities likely to shape MS care in the coming years.

What the KOL Perspective Reveals

The research highlights several important themes across modern MS management.

High-efficacy treatment remains a major focus

High-efficacy disease-modifying therapies, earlier treatment, and prevention of disability progression are among the key advances shaping current MS management.

This reflects a broader shift in treatment thinking: beyond managing relapses toward achieving stronger long-term disease control.

Important gaps still remain

Despite major progress, current treatment options do not completely address every clinical need.

Persistent challenges include disability progression, progressive MS, treatment tolerability, and long-term disease control.

For researchers and healthcare innovators, these gaps represent important areas for continued development.

Biomarkers and advanced monitoring are gaining importance

The role of biomarkers, MRI, digital measures, and personalized medicine is becoming increasingly important in MS care.

These approaches could support more comprehensive disease monitoring and help clinicians better understand disease activity and treatment response.

Neurofilament light chain and other emerging biomarkers are also contributing to discussions around more data-driven MS management.

AI and digital health could reshape MS care

Artificial intelligence and digital health technologies are emerging as important components of the future MS ecosystem.

Potential applications include longitudinal monitoring, identifying changes in disease activity, supporting treatment decisions, and enabling more personalized approaches to care.

However, adoption will depend not only on technological capability but also on clinical validation, workflow integration, and evidence demonstrating real-world value.

Access remains as important as innovation

Developing new therapies and technologies is only part of the challenge.

Treatment cost, reimbursement, insurance restrictions, and access barriers can influence whether innovations actually reach patients.

This makes market access and implementation strategy increasingly important alongside clinical development and technological innovation.

What This Means for Healthcare and Life Sciences

For pharma, biotech, medical affairs, diagnostics, and digital health organizations, understanding expert perspectives can help identify where the MS landscape is moving.

The study points toward several strategic priorities:

Continued innovation in high-efficacy MS therapies
Greater focus on progressive MS and disability prevention
Development and validation of biomarkers and advanced monitoring
Responsible integration of AI and digital health
Stronger evidence for personalized treatment approaches
Improved treatment access and reimbursement strategies

The broader direction is clear: the future of MS management will likely depend on combining therapeutic innovation with better monitoring, data-driven decision-making, and improved access.

Explore the Full Case Study

Want to understand how experts perceive the current MS treatment landscape and where they see the next opportunities for innovation?

Read the full Multiple Sclerosis KOL Insights case study from SPER Market Research:

https://www.sperresearch.com/Case-Studies/ms-kol-insights-treatment-landscape-2026

Building AI Intelligence Systems for Pharma: A CAR-T Case Study

Ankit kumar — Thu, 13 Aug 2026 11:44:31 +0000

Most people think of CAR-T as a clinical/commercial story. It's also a genuinely interesting data engineering problem.

Think about what it takes to build a system that ingests clinical trial registries, patent filings, regulatory actions (FDA/EMA/NMPA), conference abstracts, earnings call transcripts, and real-world evidence — then turns all of that into a queryable, sourced, continuously-updated model of a therapeutic landscape.

That's the architecture behind modern pharma competitive intelligence platforms, and it's a good example of RAG + entity extraction + semantic modeling applied to a genuinely messy, high-stakes domain.

Wrote up how these systems work (and why static BI dashboards can't keep pace with a space like CAR-T) here: https://medium.com/@seosperreach/ai-car-t-intelligence-platform-2026-8d89f42734ef

Why Pharma Companies Need an AI-Powered KOL Engagement Platform in 2026

Ankit kumar — Wed, 12 Aug 2026 08:33:26 +0000

Pharma companies are dealing with growing volumes of scientific data, fragmented KOL information and increasing pressure to make engagement more measurable.

This blog explores how AI-powered platforms are changing KOL identification, tiering, network analysis and scientific engagement.

Read the full article:
https://www.sperresearch.com/Blogs/ai-kol-engagement-platform-pharma

AI-Driven Expert Intelligence for Medical Affairs

Ankit kumar — Mon, 10 Aug 2026 05:52:48 +0000

Pharmaceutical Medical Affairs teams are increasingly moving beyond static KOL databases and manual expert research.

AI-powered KOL intelligence can help connect:

KOL identification and mapping
Global healthcare expert intelligence
Scientific activity monitoring
Emerging KOL discovery
KOL segmentation and prioritization
Medical Affairs engagement planning

The important shift is not simply automating KOL research. It is creating a continuously evolving intelligence layer that helps Medical Affairs teams understand scientific influence and make more informed engagement decisions.

Our latest case study explores this transition from manual research to AI-driven expert intelligence:

https://www.apothiumai.com/Case-Studies/ai-driven-medical-affairs-intelligence

Scientific expertise evolves every day, but many pharmaceutical organizations still rely on static KOL databases that quickly become outdated.

Ankit kumar — Fri, 07 Aug 2026 10:43:08 +0000

Our latest case study explores how a Top 20 pharma company built a Living Global KOL Database powered by AI, entity resolution, and healthcare knowledge graphs to support Medical Affairs, Clinical Development, and cross-functional decision-making.

Read the full case study:
https://www.apothiumai.com/Case-Studies/living-global-kol-database-pharma

Although known for software and technology discussions, healthcare AI and digital innovation are increasingly relevant to the developer community.

Ankit kumar — Fri, 07 Aug 2026 06:26:50 +0000

Our latest case study explores how AI, digital health technologies, remote monitoring, and data-driven decision support are transforming migraine management alongside CGRP-targeted therapies.

Read the case study:
https://www.sperresearch.com/Case-Studies/kol-perception-on-migraine-management

How Leading Pharma Companies Prepare 12 Months Before a Drug Launch

Ankit kumar — Wed, 05 Aug 2026 06:33:51 +0000

A successful Drug Launch Strategy requires more than regulatory approval.

Our latest article explores:
• Pharmaceutical Launch Planning
• Medical Affairs Launch Planning
• AI-powered commercialization
• KOL engagement
• Market Access Strategy
• Cross-functional launch excellence

If you're working in pharma, biotech, Medical Affairs, or commercial strategy, this guide provides practical insights into modern Pharmaceutical Commercialization.

Read here:
https://www.apothiumai.com/Blogs/drug-launch-strategy-pharma-companies

Request a KOL Platform Demo: What to Expect Before You Book

Ankit kumar — Tue, 04 Aug 2026 09:50:36 +0000

Choosing the right KOL intelligence platform is about more than comparing feature lists. Medical Affairs and commercial teams need AI-powered KOL discovery, analytics dashboards, network mapping, and actionable insights that support evidence-based decisions.

Our latest article explores what a modern KOL Platform Demo should include, the questions to ask vendors, and the capabilities organizations should evaluate before investing in a solution.

Read the full guide:
https://industrycompetitiveanalysis.blogspot.com/2026/08/request-kol-platform-demo.html

AI Platform for Healthcare Professional Analytics: Why It Matters for Medical Affairs

Ankit kumar — Tue, 04 Aug 2026 06:59:44 +0000

Artificial Intelligence is transforming healthcare beyond diagnostics and clinical workflows. One of the fastest-growing applications is Healthcare Professional Analytics, where AI helps pharmaceutical and life sciences organizations identify Key Opinion Leaders (KOLs), analyze scientific influence, and strengthen Medical Affairs strategies.

In this article, you'll learn about:

AI-powered KOL Mapping Software
Healthcare Professional Analytics Platforms
Scientific Expert Discovery
Medical Affairs Analytics
Enterprise KOL Intelligence
Emerging AI trends in pharmaceutical analytics

Read the complete article:
https://www.sperresearch.com/Blogs/ai-platform-healthcare-professional-analytics

How are biologics, AI, and precision medicine changing lupus management?

Ankit kumar — Mon, 03 Aug 2026 07:19:32 +0000

We recently published a case study summarizing perspectives from 50 Key Opinion Leaders across the US and Europe. The report explores advances in Systemic Lupus Erythematosus treatment, biomarker-guided therapies, AI-supported care, digital health technologies, implementation barriers, and future trends.

If you're interested in rheumatology, autoimmune diseases, or healthcare innovation, I'd love to hear your thoughts.

Case study:
https://www.sperresearch.com/Case-Studies/kol-perception-lupus-management

How AI-Powered KOL Intelligence Is Transforming Medical Affairs Planning

Ankit kumar — Fri, 31 Jul 2026 11:27:33 +0000

Medical Affairs teams are managing more scientific data than ever before, making traditional KOL identification methods increasingly inefficient.

In this case study, we explore how a global pharmaceutical company implemented AI-Powered KOL Intelligence to improve Medical Affairs Planning, automate KOL identification, strengthen Global KOL Mapping, and support better scientific decision-making across international teams.

Read the full case study:
https://www.apothiumai.com/Case-Studies/ai-powered-kol-intelligence-medical-affairs-planning

How Precision Medicine, Biologics, and AI Are Transforming Psoriasis Care

Ankit kumar — Fri, 31 Jul 2026 06:50:05 +0000

The future of psoriasis and psoriatic arthritis management extends beyond new therapies. It is increasingly driven by biomarker-guided treatment, AI-enabled clinical decision support, precision dermatology, and digital health technologies.

Our latest case study explores how leading Key Opinion Leaders view these emerging trends and what they mean for pharmaceutical companies, healthcare providers, and MedTech innovators.

Read the complete case study:
https://www.sperresearch.com/Case-Studies/psoriasis-psoriatic-arthritis-kol-insights